FDA approves AMI's Gastromark agent
The Food and Drug Administration has approved a new drug applicationfor Gastromark, a gastrointestinal MRI contrast agent developedby Advanced Magnetics of Cambridge, MA. Gastromark is a superparamagneticoral contrast agent that has been licensed to
The Food and Drug Administration has approved a new drug application
for Gastromark, a gastrointestinal MRI contrast agent developed
by Advanced Magnetics of Cambridge, MA. Gastromark is a superparamagnetic
oral contrast agent that has been licensed to Mallinckrodt Medical
of St. Louis. The agent is marketed in Western Europe by Guerbet
under the trade name Lumirem. Gastromark will be priced at about
$25 per 300 mL, according to Jerome Goldstein, president and CEO
of Advanced Magnetics. Either 600 or 900 mL will likely be administered,
bringing the total cost to between $50 and $75 per patient.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
